Actinic Keratosis Drugs Market Report 2025 (Global Edition)

Global Actinic Keratosis Drugs Market Report 2025 Market Size Split by Therapy Outlook: (Topical, Photodynamic Therapy, Surgery), by Drug-Class Outlook: (Nucleoside Metabolic Inhibitor, NSAIDs, Immune...

Actinic Keratosis Drugs Market Report Description

We have various report editions of Actinic Keratosis Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Actinic Keratosis Drug Market

The actinic keratosis drugs industry is highly competitive, with many companies vying for a larger share of the pie through the development of novel treatments to meet this rising demand. Prominent players in the market are developing new topical therapies, photodynamic treatments, and oral medications. They fortify their positions through strategic efforts like mergers and collaborations, and they introduce better and more effective solutions through investment in R&D. Additionally, companies are concentrating on expanding their product lines and geographic reach in response to the increasing number of instances caused by an ageing population and more sun exposure.

In November 2024, Novartis shared encouraging findings from the landmark Phase III ASC4FIRST study as a late-breaking abstract at the 2024 ASCO meeting. In patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), Scemblix (asciminib) showed better major molecular response (MMR) rates at week 48 compared to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib, and bosutinib, with imatinib alone being the lowest. (Source: https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml) In February 2023, Almirall S.A., a global pharmaceutical company that focuses on medical dermatology, and the Centre for Genomic Regulation (CRG), an international biomedical research centre with its main office in Barcelona, agreed to work together on new research projects. The group’s goal is to find molecular pathways and signs that are unique to atopic dermatitis (AD). Discovering new ways to treat this complicated disease could be made possible by learning more about how it works. (Source: https://www.almirall.com/newsroom/news/almirall-announces-partnership-with-the-centre-for-genomic-regulation-crg-to-identify-biomarkers-for-novel-atopic-dermatitis-treatments In January 2024, LEO Pharma, a world leader in medical dermatology, hired Dr Lars Erik Vølund Kristensen to lead the search for new ideas from outside the company, encourage collaboration, and find new growth possibilities. He is the third professor from the University of Copenhagen to join LEO Pharma since the beginning of 2023. This shows that the company is serious about giving people with unmet medical needs new and useful dermatology products. (Source: https://www.leo-pharma.com/media-center/news/2024-recognized-professor-joins-leo-pharma-to-accelerate-external-innovation)

Top Companies Market Share in Actinic Keratosis Drugs Industry: (In no particular order of Rank)

• Almirall S.A.
• LEO Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GALDERMA
• Ortho Dermatologics (Bausch Health Companies Inc.)
• BIOFRONTERA AG
• Hill Dermaceuticals
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Actinic Keratosis Drug Market

Which Region Dominates the Actinic Keratosis Drug Market in 2024?

According to Cognitive Market Research, North America currently dominates the actinic keratosis drugs market, and the region is expected to have significant growth during the projected period. This is due to the region's robust healthcare system, heightened public consciousness regarding skin health, and a high incidence of actinic keratosis. The region’s market is expected to grow at a significant rate during the projected period due to factors such as an older population that is more prone to actinic keratosis and new treatment options.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR) due to better healthcare facilities, more people paying attention to skin health, and more cases of actinic keratosis caused by more sun exposure. In addition, rising incomes and more access to healthcare also drive the region's market growth.

The current report Scope analyzes Actinic Keratosis Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Actinic Keratosis Drugs

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2645.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Actinic keratosis drug market with a market size of USD 2087.44 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. The U.S. market's stringent governmental regulations against skin care.
• The Canada Actinic keratosis drug market had a market share of USD 317.48 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Canada’s rising awareness among the population.
• The Mexico Actinic keratosis drug market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 240.76 million in 2024.

Europe Actinic Keratosis Drugs

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1984.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom Actinic keratosis drug market had a market share of USD 333.36 million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. In the UK, Actinic keratosis drug sales witness an upswing due to the increasing focus on health care.
• The France Actinic keratosis drug market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 182.55 million in 2024.
• According to Cognitive Market Research, the German Actinic keratosis drug market size was valued at USD 392.88 million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. In Germany, Actinic keratosis drugs surged due to the increased focus of the drug manufacturers and major market players.
• The Italy Actinic keratosis drug market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 170.65 million in 2024.
• The Russia Actinic keratosis drug market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD 307.56 million in 2024.
• The Spain Actinic keratosis drug market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 162.71 million in 2024
• The Luxembourg Actinic keratosis drug market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 61.51 million in 2024.
• The Portugal Actinic keratosis drug market is projected to witness growth at a CAGR of 3.3% during the forecast period, with a market size of USD 41.67 million in 2024.
• The Greece Actinic keratosis drug market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 23.81 million in 2024.
• The Rest of Europe's Actinic keratosis drug market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 307.56 million in 2024.

Asia Pacific Actinic Keratosis Drugs

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 1521.27 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Actinic keratosis drug market size was valued at USD 684.57 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Actinic keratosis drugs surged in China due to the presence of major market players.
• The Japan Actinic keratosis drug market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 209.93 million in 2024.
• The India Actinic keratosis drug market had a market share of USD 182.55 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. India's rising awareness among the population.
• The South Korean Actinic keratosis drug market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 152.13 million in 2024.
• The Australian Actinic keratosis drug market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 79.11 million in 2024.
• The Southeast Asia Actinic keratosis drug market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 104.97 million in 2024.
• The Rest of Asia Pacific Actinic keratosis drug market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 108.01 million in 2024.

South America Actinic Keratosis Drugs

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 330.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Actinic keratosis drug market size was valued at USD 141.54 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Actinic keratosis drugs flourished in Brazil due to increasing demand for skin care.
• Argentina's Actinic keratosis drug market had a market share of USD 55.56 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. Argentina's rising personal disposable income .
• Colombia Actinic keratosis drug market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 29.43 million in 2024.
• Peru Actinic keratosis drug market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 27.12 million in 2024.
• Chile Actinic keratosis drug market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 23.81 million in 2024.
• The Rest of Latin America's Actinic keratosis drug market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 53.24 million in 2024.

Middle East Actinic Keratosis Drugs

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 132.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031..

• The GCC Countries Actinic keratosis drug market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 56.52 million in 2024. Actinic keratosis drug sales flourish due to the presence of major market players.
• The Egypt Actinic keratosis drug market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 13.89 million in 2024.
• The South Africa Actinic keratosis drug market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 20.90 million in 2024. Actinic keratosis drug sales flourished in South Africa due to increasing demand and regulatory support.
• The Turkey Actinic keratosis drug market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 11.38 million in 2024.
• The Nigeria Actinic keratosis drug market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 13.89 million in 2024.
• The Rest of the MEA Actinic keratosis drug market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 15.61 million in 2024.

Actinic Keratosis Drugs Market Analysis

How are Segments Performing in the Global Actinic Keratosis Drug Market?

Actinic Keratosis Drug Market Therapy Segment Analysis

According to Cognitive Market Research, topical actinic keratosis drugs are likely to dominate the actinic keratosis drug market over the forecast period owing to their effectiveness in treating early-stage skin lesions directly, their lack of invasiveness, and their relative ease of use. Additionally, because of their low toxicity and relative ease of application, topical therapies are ideal for use in outpatient settings. Moreover, the demand for topical therapies in this market is being propelled by developments in formulation as well as an increase in patient preference for at-home treatments.

Photodynamic therapy is the fastest-growing segment in the actinic keratosis drug market because of its minimal adverse effects, great efficacy, and focused strategy. Patients like this therapy because it eliminates aberrant cells selectively while protecting good tissue. Additionally, photodynamic therapy is in high demand as a minimally invasive treatment for actinic keratosis due to expanding awareness, improvements in light-based technology, and the condition’s increasing prevalence.

{type_end} Drug Class_desc {application_start}

Actinic Keratosis Drug Market Drug Class Segment Analysis

According to Cognitive Market Research, the nucleoside metabolic segment holds the largest share of the market because it effectively targets cellular abnormalities and inhibits the progression of lesions. Their well-documented safety profiles and high therapeutic efficacy make these treatments top choices. Additionally, demand is being driven by an increase in both R&D efforts and the incidence of actinic keratosis.

In the actinic keratosis drug market, the Photoenhancers sector has been expanding at a rapid pace because of its capacity to enhance the efficacy of photodynamic treatment. The use of photo enhancers improves treatment outcomes and decreases dosage requirements by increasing the absorption of light by target cells. Moreover, innovations in light-based therapies and the growing need for effective, minimally invasive treatments are fueling the sector’s rapidly growing demand for actinic keratosis drugs.

{application_end} End-use_desc {fourth_seg_desc_start}

Actinic Keratosis Drug Market End-use Segment Analysis

According to Cognitive Market Research, the hospital segment dominates the market due to the abundance of dermatology clinics, cutting-edge treatments, and competent doctors and nurses. Photodynamic treatments and prescription drugs are two of the best therapies offered by hospitals, which draw patients looking for thorough and dependable medical attention. The market is being propelled forward by rising patient desire for in-hospital therapies and rising generalized awareness.

Private clinics are projected to be the fastest-growing segment in the actinic keratosis drug market. Because they are easy to reach, provide individualized attention, and have reduced wait periods. The segment is expected to have substantial expansion throughout the forecast period, driven by patients’ preference for easy treatment choices, such as topical therapies and photodynamic treatments, which private clinics offer.

{fourth_seg_desc_end} tenth_seg_desc {tenth_seg_desc_start} Conclusion

• The global Actinic keratosis drug market will expand significantly by 5.00% CAGR between 2024 and 2031.
• Topical actinic keratosis drugs are expected to dominate the actinic keratosis drug market over the forecast period. Because they are less invasive, more convenient, and preferred by patients.
• The hospital’s segment has the biggest market share propelled by expert medical attention, cutting-edge treatment choices, and the demand for thorough, dependable healthcare among patients.

{tenth_seg_desc_end} 8th FAQ Frequently asked questions regarding the global actinic keratosis drug market {faq_start} {faq}What is the market size for the actinic keratosis drug market in 2024? {ans}The global market size for actinic keratosis drug in 2024 is USD 6614.2 million. {faq}What is the growth rate for the actinic keratosis drug market over the forecast period? {ans}The global actinic keratosis drug market is expected to grow with a CAGR of 5.00% over the projected period. {faq}Which is the leading region of the market for actinic keratosis drugs? {ans}North America held a significant global actinic keratosis drug market revenue share in 2024. {faq}Which region is projected to detect the fastest growth in the actinic keratosis drug market over the forecast period? {ans}Asia-Pacific will witness the fastest growth of the global actinic keratosis drug market over the coming years. {faq}Which country will be leading in the actinic keratosis drug market in 2024? {ans}The US had the most significant global actinic keratosis drug market revenue share in 2024. {faq}What are the key drivers for the growth of the actinic keratosis drug market? {ans} The main driver of the growth of the actinic keratosis drug market is an ageing population; more sun exposure and heightened awareness are driving up the incidence of actinic keratosis, which in turn is increasing the demand for the actinic keratosis drug market. {faq}Which is the significant actinic keratosis drug market segment by End use? {ans}The hospital’s category dominates the market. {faq_end} 11th Regional Insights {north_america_meta_description_start} North America’s Actinic keratosis drug market size will be USD 2645.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031. North America has emerged as a prominent participant, and its sales revenue is estimated to reach USD 3592.4 Million by 2031. This growth is mainly attributed to the increasing ageing population and urbanization. {north_america_meta_description_end} {north_america_report_title_start} North America’s Actinic keratosis drug market size will be USD 2645.68 million in 2024. {north_america_report_title_end} {north_america_start}

According to Cognitive Market Research, the global Actinic keratosis drug market size was estimated at USD 6614.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2645.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Actinic keratosis drug market with a market size of USD 2087.44 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. The U.S. market's stringent governmental regulations against skin care.
• The Canada Actinic keratosis drug market had a market share of USD 317.48 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Canada’s rising awareness among the population.
• The Mexico Actinic keratosis drug market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 240.76 million in 2024.

{north_america_end} {north_america_report_scope_start} North

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Actinic Keratosis Drugs Industry. Request a Free Sample PDF!

Drug-Class Outlook: Segment Analysis of Actinic Keratosis Drugs Market

This report analyzes revenue growth in the pharma and healthcare industry at global, regional, and national levels, highlighting trends and opportunities for each application. It explores how sectors like pharmaceuticals, therapy, and healthcare monitoring use innovations to address healthcare needs. Key factors include market size, revenue contributions, technological advancements (e.g., AI-driven diagnostics), and regulatory considerations. The report also covers the value chain, identifying key players and processes within the industry. For more information, please request a sample or contact our research team.

Some of the key Drug-Class Outlook: of Actinic Keratosis Drugs are:

• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion